• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Veramark Technologies

Veramark Technologies

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)

    Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)

  2. New Zealand Business Confidence Eases in November

    New Zealand Business Confidence Eases in November

  3. Australian Full Time Employment Rises in Oct

    Australian Full Time Employment Rises in Oct

  4. Australia Wage Growth Falls to Record Low

    Australia Wage Growth Falls to Record Low

  5. Water-Based Personal Lubricant – Market Trends and Forecasts From Technavio

    Water-Based Personal Lubricant – Market Trends and Forecasts From Technavio

  6. Big-Name Brands Go to War Over Department Store Sales -- WSJ

    Big-Name Brands Go to War Over Department Store Sales -- WSJ

  7. LIVESTOCK HIGHLIGHTS: Top Stories of the Day

    LIVESTOCK HIGHLIGHTS: Top Stories of the Day

  8. Our Outlook for Consumer Cyclical Stocks

    The U.S. economy is in decent shape, but we are being even more selective given recent outperformance.

  9. Our Outlook for Consumer Cyclical Stocks

    As macro headwinds mount, we would look for a larger valuation discount among consumer cyclical names.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.